NCT06079320 - A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Respiratory Syncytial Virus Infection

Interventions

DRUG

Sisunatovir

Participants will receive tablets from Day 1 to Day 5

DRUG

Placebo

Participants will receive matching placebo tablets from Day 1 to Day 5

Trial Locations (19)

10455

CHEAR Center LLC, The Bronx

11220

DM Clinical Research - AOM, Brooklyn

15236

Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18), Pittsburgh

32757

Adult Medicine of Lake County, Inc., Mt. Dora

Adult Medicine of Lake County, Mt. Dora

33184

De La Cruz Research Center, LLC, Miami

59701

Mercury Street Medical Group, PLLC, Butte

60453

Accellacare - DuPage, Oak Lawn

75149

Salma Mazhar, MD PA, Mesquite

SMS Clinical Research, Mesquite

75230

Zenos Clinical Research, Dallas

77043

Biopharma Informatic, LLC, Houston

92683

National Institute of Clinical Research, Westminster

92844

National Institute of Clinical Research, Garden Grove

201100

Shanghai Minhang District Central Hospital, Shanghai

302039

Maharaja Agrasen Superspeciality Hospital, Jaipur

210-0852

Koukankai Koukan Clinic, Kawasaki-Shi

610-0113

National Hospital Organization Minami Kyoto Hospital, Jōyō

901-0493

Nanbu Tokushukai Hospital, Shimajiri